Geron (NASDAQ:GERN) Sees Strong Trading Volume – What’s Next?

Geron Co. (NASDAQ:GERN) saw an uptick in trading volume on Thursday . 11,157,844 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 10,309,587 shares.The stock last traded at $4.28 and had previously closed at $4.27.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GERN shares. StockNews.com upgraded shares of Geron to a “sell” rating in a research report on Monday, August 5th. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Geron in a research report on Friday, August 9th. Scotiabank initiated coverage on Geron in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 target price for the company. Finally, HC Wainwright began coverage on Geron in a research report on Tuesday. They issued a “buy” rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $7.05.

Geron Stock Down 0.2 %

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.61 and a quick ratio of 3.60. The stock has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $4.30.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The firm had revenue of $0.88 million during the quarter, compared to the consensus estimate of $0.34 million. During the same quarter in the previous year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 2941.4% on a year-over-year basis. As a group, research analysts predict that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Geron

Institutional investors have recently modified their holdings of the company. National Bank of Canada FI increased its stake in Geron by 1,200.0% in the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,000 shares during the last quarter. Crewe Advisors LLC grew its holdings in Geron by 870.0% in the 1st quarter. Crewe Advisors LLC now owns 9,700 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 8,700 shares during the period. Kingsview Wealth Management LLC acquired a new position in shares of Geron during the 1st quarter valued at about $34,000. American Trust purchased a new position in shares of Geron during the 1st quarter worth about $38,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Geron during the 3rd quarter worth about $62,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.